HRP20110970T1 - 3-supstituirani-[1,2,3]-benzotriazinonski spoj za poboljšanje glutamatergičnih sinaptičkih odgovora - Google Patents
3-supstituirani-[1,2,3]-benzotriazinonski spoj za poboljšanje glutamatergičnih sinaptičkih odgovora Download PDFInfo
- Publication number
- HRP20110970T1 HRP20110970T1 HR20110970T HRP20110970T HRP20110970T1 HR P20110970 T1 HRP20110970 T1 HR P20110970T1 HR 20110970 T HR20110970 T HR 20110970T HR P20110970 T HRP20110970 T HR P20110970T HR P20110970 T1 HRP20110970 T1 HR P20110970T1
- Authority
- HR
- Croatia
- Prior art keywords
- treatment
- compound according
- compound
- production
- drug
- Prior art date
Links
- -1 3-substituted-[1,2,3]-benzotriazinone compound Chemical class 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 230000000848 glutamatergic effect Effects 0.000 title 1
- 230000009782 synaptic response Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 17
- 239000002253 acid Substances 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 6
- 102000003678 AMPA Receptors Human genes 0.000 claims 3
- 108090000078 AMPA Receptors Proteins 0.000 claims 3
- 230000002964 excitative effect Effects 0.000 claims 3
- 230000003528 hypoglutamatergic effect Effects 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 210000000225 synapse Anatomy 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 230000003920 cognitive function Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- JHCFQXNWYDLBOG-UHFFFAOYSA-N 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione Chemical compound FC1=CC=CC(CCN2C(C3=CC=4OCN(C(=O)C=4C=C3N=N2)C2CC2)=O)=C1 JHCFQXNWYDLBOG-UHFFFAOYSA-N 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000001914 Fragile X syndrome Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 230000006399 behavior Effects 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 210000001577 neostriatum Anatomy 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000000698 schizophrenic effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Spoj, naznačen time, da ima formulu: ili farmaceutski prihvatljivu adicijsku sol njegove kiseline ili lužine. Patent sadrži još 15 patentnih zahtjeva.
Claims (16)
1. Spoj, naznačen time, da ima formulu:
[image]
ili farmaceutski prihvatljivu adicijsku sol njegove kiseline ili lužine.
2. Spoj formule prema patentnom zahtjevu 1, naznačen time, da je:
8-ciklopropil-3-[2-(3-fluorofenil)etil]-7,8-dihidro-3H-[1,3]oksazino[6,5-g][1,2,3]benzotriazin-4,9-dion ili farmaceutski prihvatljiva adicijska sol njegove kiseline ili lužine.
3. Spoj prema patentnom zahtjevu 1 ili 2, naznačen time, da je za uporabu u liječenju hipoglutamatergičnog stanja ili pomanjkanja broja ili jačine ekscitatornih sinapsi ili broja AMPA receptora, tako da su pamćenje ili druge kognitivne funkcije oštećene.
4. Spoj prema patentnom zahtjevu 1 ili 2, naznačen time, da je za uporabu u liječenju hipoglutamatergičnog stanja ili pomanjkanja broja ili jačine ekscitatornih sinapsi ili broja AMPA receptora, tako da se javlja kortikalno/striatumski debalans koji dovodi do Schizofrenije ili Schizofrenijskog ponašanja.
5. Spoj prema patentnom zahtjevu 1 ili 2, naznačen time, da je za uporabu u liječenju Schizofrenije.
6. Spoj prema patentnom zahtjevu 1 ili 2, naznačen time, da je za uporabu u liječenju Parkinsonove bolesti.
7. Spoj prema patentnom zahtjevu 1 ili 2, naznačen time, da je uporabu u liječenju Alzheimerove bolesti.
8. Farmaceutski pripravak koji sadrži učinkovitu količinu spoja iz bilo kojeg od patentnih zahtjeva 1-2, naznačen time, da je u kombinaciji s farmaceutski prihvatljivim nosačem, aditivom ili ekscipijensom.
9. Pripravak u skladu s patentnim zahtjevom 8, naznačen time, da rečeni spoj sadrži oko 0.5% do oko 75% od težine rečenog pripravka i rečenog nosača, aditiva ili ekscipijensa koji sadrže oko 25% do oko 95% rečenog pripravka.
10. Uporaba spoja prema bilo kojem od patentnih zahtjeva 1-2, naznačena time, da se koristi za proizvodnju lijeka za uporabu u liječenju sisavaca, kada pojedinac pati od hipoglutamatergilnog stanja ili pomanjkanja broja ili jačine ekscitatornih sinapsi ili broja AMPA receptora, tako da su pamćenje ili neke druge kognitivne funkcije oštećene.
11. Uporaba spoja u skladu bilo kojim od patentnih zahtjeva 1 i 2, naznačena time, da se koristi za proizvodnju lijeka za uporabu u liječenju schizofrenije.
12. Uporaba spoja u skladu bilo kojim od patentnih zahtjeva 1 i 2, naznačena time, da se koristi za proizvodnju lijeka za uporabu u liječenju Parkinsonove bolesti.
13. Uporaba spoja u skladu bilo kojim od patentnih zahtjeva 1 i 2, naznačena time, da se koristi za proizvodnju lijeka za uporabu u liječenju ADHD-a.
14. Uporaba spoja u skladu bilo kojim od patentnih zahtjeva 1 i 2, naznačena time, da se koristi za proizvodnju lijeka za uporabu u liječenju Rettovog sindroma.
15. Uporaba spoja u skladu bilo kojim od patentnih zahtjeva 1 i 2, naznačena time, da se koristi za proizvodnju lijeka za uporabu u liječenju Fragile-X sindroma.
16. Uporaba spoja u skladu bilo kojim od patentnih zahtjeva 1 i 2, naznačena time, da se koristi za proizvodnju lijeka za uporabu u liječenju Alzheimerove bolesti.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87850307P | 2007-01-03 | 2007-01-03 | |
| US92143307P | 2007-04-02 | 2007-04-02 | |
| PCT/US2007/026416 WO2008085506A1 (en) | 2007-01-03 | 2007-12-28 | 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110970T1 true HRP20110970T1 (hr) | 2012-01-31 |
Family
ID=39608956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110970T HRP20110970T1 (hr) | 2007-01-03 | 2011-12-23 | 3-supstituirani-[1,2,3]-benzotriazinonski spoj za poboljšanje glutamatergičnih sinaptičkih odgovora |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US8173644B2 (hr) |
| EP (1) | EP2144506B1 (hr) |
| JP (1) | JP5139446B2 (hr) |
| CN (1) | CN101616592B (hr) |
| AP (1) | AP2502A (hr) |
| AR (1) | AR064740A1 (hr) |
| AT (1) | ATE527269T1 (hr) |
| AU (1) | AU2007342365B2 (hr) |
| BR (1) | BRPI0720749A2 (hr) |
| CA (1) | CA2674460C (hr) |
| CR (1) | CR10906A (hr) |
| CU (1) | CU23804B7 (hr) |
| CY (1) | CY1112493T1 (hr) |
| DK (1) | DK2144506T3 (hr) |
| EA (1) | EA017437B1 (hr) |
| EC (1) | ECSP099499A (hr) |
| ES (1) | ES2374995T3 (hr) |
| GE (1) | GEP20125438B (hr) |
| GT (1) | GT200900189A (hr) |
| HK (1) | HK1140105A1 (hr) |
| HN (1) | HN2009001268A (hr) |
| HR (1) | HRP20110970T1 (hr) |
| IL (1) | IL199651A (hr) |
| MA (1) | MA31160B1 (hr) |
| ME (1) | ME00819B (hr) |
| MX (1) | MX2009007242A (hr) |
| MY (1) | MY154877A (hr) |
| NI (1) | NI200900131A (hr) |
| NZ (1) | NZ578293A (hr) |
| PL (1) | PL2144506T3 (hr) |
| PT (1) | PT2144506E (hr) |
| RS (1) | RS52108B (hr) |
| SG (1) | SG163545A1 (hr) |
| SI (1) | SI2144506T1 (hr) |
| SV (1) | SV2009003322A (hr) |
| TN (1) | TN2009000277A1 (hr) |
| WO (1) | WO2008085506A1 (hr) |
| ZA (1) | ZA200904826B (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2114158B1 (en) * | 2007-01-03 | 2012-08-08 | Cortex Pharmaceuticals, Inc. | 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses |
| KR101599661B1 (ko) | 2007-05-17 | 2016-03-03 | 코텍스 파마슈티칼스, 인크. | 글루타메이트에 의한 시냅스 반응을 향상시키기 위한 이치환된 아미드 화합물 |
| US8168632B2 (en) | 2007-08-10 | 2012-05-01 | Cortex Pharmaceuticals, Inc. | Bicyclic amide derivatives for the treatment of respiratory disorders |
| SG163526A1 (en) | 2007-08-10 | 2010-08-30 | Cortex Pharma Inc | Bicyclic amides for enhancing glutamatergic synaptic responses |
| US20110257186A1 (en) * | 2010-04-15 | 2011-10-20 | Staubli Ursula V | Compositions and methods for treating visual disorders |
| US9242938B2 (en) | 2011-11-22 | 2016-01-26 | Beijing Medisan Technology Co., Ltd | Glycine reuptake inhibitor and use thereof |
| FR3019464B1 (fr) | 2014-04-07 | 2016-05-06 | Servier Lab | Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent |
| FR3034019B1 (fr) * | 2015-03-26 | 2017-03-17 | Servier Lab | Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent |
| MX2017016875A (es) | 2015-06-26 | 2018-04-24 | Takeda Pharmaceuticals Co | Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores de receptor muscarinico colinergico m1. |
| CN106226509B (zh) * | 2016-08-12 | 2019-09-06 | 中国人民解放军第四军医大学 | 一种在小鼠前扣带回皮层诱发dse现象的方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3723436A (en) * | 1971-02-25 | 1973-03-27 | Sun Oil Co | Process for aromatic lactams |
| DK623586A (da) * | 1985-12-27 | 1987-06-28 | Eisai Co Ltd | Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne |
| FR2597103B1 (fr) * | 1986-04-15 | 1988-12-16 | Provesan Sa | Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde |
| ATE215079T1 (de) | 1992-07-24 | 2002-04-15 | Univ California | Arzneimittel, die den durch ampa rezeptoren vermittelten synaptischen respons erhöhen |
| US5962477A (en) * | 1994-04-12 | 1999-10-05 | Adolor Corporation | Screening methods for cytokine inhibitors |
| DK0709384T3 (da) * | 1994-10-31 | 1999-08-23 | Merck Patent Gmbh | Benzylpiperidinderivater med høj affinitet til aminosyrereceptorers bindingssteder |
| US5650409A (en) * | 1995-06-02 | 1997-07-22 | Cortex Pharmaceuticals, Inc. | Benzoyl piperidines/pyrrolidines for enhancing synaptic response |
| US5736543A (en) * | 1996-04-03 | 1998-04-07 | The Regents Of The University Of California | Benzoxazines for enhancing synaptic response |
| AU4416197A (en) | 1996-09-17 | 1998-04-14 | Regents Of The University Of California, The | Positive ampa receptor modulation to enhance brain neurotrophic factor expression |
| US6110935A (en) * | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
| US5985871A (en) | 1997-12-24 | 1999-11-16 | Cortex Pharmaceuticals, Inc. | Benzoxazine compounds for enhancing synaptic response |
| EP1071426A2 (en) | 1998-02-18 | 2001-01-31 | Neurosearch A/S | Novel compounds and their use as positive ampa receptor modulators |
| US6713474B2 (en) * | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| US6303542B1 (en) * | 2000-08-18 | 2001-10-16 | Rohm And Haas Company | Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones |
| NZ532368A (en) * | 2001-11-26 | 2006-10-27 | Cortex Pharma Inc | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses |
| JP2003238555A (ja) * | 2002-02-20 | 2003-08-27 | Sumitomo Pharmaceut Co Ltd | 細胞死抑制剤 |
| AUPS255202A0 (en) * | 2002-05-27 | 2002-06-13 | Monash University | Agents and methods for the treatment of disorders associated with motor neuron degeneration |
| JP2006516283A (ja) * | 2003-01-13 | 2006-06-29 | コーテックス ファーマシューティカルズ， インコーポレイテッド | 睡眠不足とストレスに起因する知覚衰退の処置方法 |
| GB0317482D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| CN1897950A (zh) * | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| EP2114158B1 (en) * | 2007-01-03 | 2012-08-08 | Cortex Pharmaceuticals, Inc. | 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses |
| KR101599661B1 (ko) * | 2007-05-17 | 2016-03-03 | 코텍스 파마슈티칼스, 인크. | 글루타메이트에 의한 시냅스 반응을 향상시키기 위한 이치환된 아미드 화합물 |
| SG163526A1 (en) | 2007-08-10 | 2010-08-30 | Cortex Pharma Inc | Bicyclic amides for enhancing glutamatergic synaptic responses |
| US20100267728A1 (en) * | 2007-09-20 | 2010-10-21 | Cortex Pharmaceuticals, Inc. | 3-substituted-1,2,3-triazin-4-one's and 3 substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses |
-
2007
- 2007-12-28 NZ NZ578293A patent/NZ578293A/en not_active IP Right Cessation
- 2007-12-28 SI SI200730806T patent/SI2144506T1/sl unknown
- 2007-12-28 ME MEP-2009-238A patent/ME00819B/me unknown
- 2007-12-28 ZA ZA200904826A patent/ZA200904826B/xx unknown
- 2007-12-28 BR BRPI0720749-2A patent/BRPI0720749A2/pt not_active Application Discontinuation
- 2007-12-28 RS RS20110587A patent/RS52108B/en unknown
- 2007-12-28 CA CA2674460A patent/CA2674460C/en not_active Expired - Fee Related
- 2007-12-28 MX MX2009007242A patent/MX2009007242A/es active IP Right Grant
- 2007-12-28 SG SG201004695-1A patent/SG163545A1/en unknown
- 2007-12-28 AP AP2009004931A patent/AP2502A/xx active
- 2007-12-28 EA EA200900925A patent/EA017437B1/ru not_active IP Right Cessation
- 2007-12-28 JP JP2009544857A patent/JP5139446B2/ja not_active Expired - Fee Related
- 2007-12-28 CN CN2007800508375A patent/CN101616592B/zh not_active Expired - Fee Related
- 2007-12-28 WO PCT/US2007/026416 patent/WO2008085506A1/en active Application Filing
- 2007-12-28 ES ES07868093T patent/ES2374995T3/es active Active
- 2007-12-28 PT PT07868093T patent/PT2144506E/pt unknown
- 2007-12-28 AU AU2007342365A patent/AU2007342365B2/en not_active Ceased
- 2007-12-28 US US12/448,784 patent/US8173644B2/en not_active Expired - Fee Related
- 2007-12-28 EP EP07868093A patent/EP2144506B1/en active Active
- 2007-12-28 PL PL07868093T patent/PL2144506T3/pl unknown
- 2007-12-28 GE GEAP200711384A patent/GEP20125438B/en unknown
- 2007-12-28 MY MYPI20092796A patent/MY154877A/en unknown
- 2007-12-28 DK DK07868093.1T patent/DK2144506T3/da active
- 2007-12-28 AT AT07868093T patent/ATE527269T1/de active
-
2008
- 2008-01-03 AR ARP080100022A patent/AR064740A1/es not_active Application Discontinuation
-
2009
- 2009-06-30 TN TNP2009000277A patent/TN2009000277A1/fr unknown
- 2009-07-01 NI NI200900131A patent/NI200900131A/es unknown
- 2009-07-02 IL IL199651A patent/IL199651A/en active IP Right Grant
- 2009-07-02 GT GT200900189A patent/GT200900189A/es unknown
- 2009-07-02 SV SV2009003322A patent/SV2009003322A/es unknown
- 2009-07-02 CR CR10906A patent/CR10906A/es not_active Application Discontinuation
- 2009-07-03 CU CU20090117A patent/CU23804B7/es active IP Right Grant
- 2009-07-03 HN HN2009001268A patent/HN2009001268A/es unknown
- 2009-07-07 EC EC2009009499A patent/ECSP099499A/es unknown
- 2009-07-31 MA MA32135A patent/MA31160B1/fr unknown
-
2010
- 2010-06-29 HK HK10106349.3A patent/HK1140105A1/xx not_active IP Right Cessation
-
2011
- 2011-12-23 HR HR20110970T patent/HRP20110970T1/hr unknown
- 2011-12-28 CY CY20111101287T patent/CY1112493T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110970T1 (hr) | 3-supstituirani-[1,2,3]-benzotriazinonski spoj za poboljšanje glutamatergičnih sinaptičkih odgovora | |
| CY1124117T1 (el) | Ετεροκυκλικες αλκυνυλοβενζολικες ενωσεις και ιατρικες συνθεσεις και χρησεις αυτων | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| UA99309C2 (ru) | Замещенные пиперидинодигидротиенопиримидины | |
| EA201490774A1 (ru) | Новые производные оксазина и их применение при лечении заболевания | |
| EA201391029A1 (ru) | Производные оксазина и их применение при лечении неврологических нарушений | |
| GT201300179A (es) | Derivados heterociclicos novedosos y su uso en el tratamiento de trastornos neurologicos | |
| SE0402735D0 (sv) | Novel compounds | |
| MA38146B1 (fr) | Nouveaux dérivés du benzimidazole comme antagonistes ep4 | |
| EA201070841A1 (ru) | НОВЫЕ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ | |
| EA201400183A1 (ru) | Фенил-3-азабицикло[3.1.0]гекс-3-илметаноны и их применение в качестве лекарственного средства | |
| AR050952A1 (es) | Derivados de indazolona; procesos para su obtencion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta - hsd1. | |
| EA201270505A1 (ru) | Производные иминотиадиазиндиоксида в качестве ингибиторов bace, композиции на их основе, и их применение | |
| MX344308B (es) | Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso. | |
| BRPI0507309A (pt) | derivados de ácido 7-fenilamino-4quinolon-3-carboxìlico, processos para produção e seu uso como medicamento | |
| EA201101395A1 (ru) | Производные 1-гетероциклил-1,5-дигидропиразоло[3,4d]пиримидин-4-oha и их применение в качестве модуляторов pde9a | |
| HRP20170025T1 (hr) | Derivati tetrahidropirolotiazina kao inhibitori bace | |
| EA200802051A1 (ru) | Дигидротиенопиримидины для лечения воспалительных заболеваний | |
| EA201590449A1 (ru) | Перорально вводимая лекарственная композиция | |
| MX2011007774A (es) | Derivados de isoxazol-isoxazol e isoxazol-isotiazol. | |
| ECSP088293A (es) | Inhibidores de gamma secretasa, de sulfonamido n-cíclico puenteado | |
| HRP20160674T1 (hr) | Tetrahidropirolotiazinski spojevi | |
| BR112015025804A2 (pt) | derivados de glutarimida, uso dos mesmos, composição farmacêutica com base neles e métodos para a produção de derivados de glutarimida | |
| EA202091641A1 (ru) | 2,4,6,7-ТЕТРАГИДРОПИРАЗОЛО[4,3-d]ПИРИМИДИН-5-ОНОВЫЕ ПРОИЗВОДНЫЕ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА C5a ДЛЯ ЛЕЧЕНИЯ ВАСКУЛИТА И ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ | |
| HRP20210010T1 (hr) | Injekcijske farmaceutske formulacije lefamulina |